Galera Therapeutics (GRTX) Insider Trading & Ownership $0.04 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Galera Therapeutics (NASDAQ:GRTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.90%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$267,150.00Number OfInsiders Selling(Last 3 Years)0 Get GRTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Galera Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GRTX Insider Buying and Selling by Quarter Ad StockEarnings9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)Get the Name of These AI Picks Now Galera Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/16/2023Mark BachledaInsiderBuy11,000$2.25$24,750.00 3/13/2023Chris DegnanCFOBuy10,000$1.96$19,600.00 3/10/2023Mel SorensenCEOBuy100,000$1.68$168,000.00 12/17/2021Linda WestDirectorBuy20,000$2.74$54,800.00 (Data available from 1/1/2013 forward) GRTX Insider Trading Activity - Frequently Asked Questions Who is on Galera Therapeutics's Insider Roster? The list of insiders at Galera Therapeutics includes Chris Degnan, Linda West, Mark Bachleda, and Mel Sorensen. Learn more on insiders at GRTX. What percentage of Galera Therapeutics stock is owned by insiders? 6.90% of Galera Therapeutics stock is owned by insiders. Learn more on GRTX's insider holdings. Which Galera Therapeutics insiders have been buying company stock? The following insiders have purchased GRTX shares in the last 24 months: Chris Degnan ($19,600.00), Mark Bachleda ($24,750.00), and Mel Sorensen ($168,000.00). How much insider buying is happening at Galera Therapeutics? Insiders have purchased a total of 121,000 GRTX shares in the last 24 months for a total of $212,350.00 bought. Galera Therapeutics Key ExecutivesDr. J. Mel Sorensen M.D. (Age 67)CEO, President & Director Compensation: $632.64kDr. Robert A. Beardsley M.B.A. (Age 62)Ph.D., Co-Founder & COO Compensation: $464.59kMr. Christopher Degnan (Age 44)Chief Financial Officer Compensation: $474.05kMs. Jennifer Evans Stacey Esq. (Age 59)Chief Legal & Compliance Officer and Secretary Ms. Andie CollierChief Regulatory & Quality Affairs OfficerMs. Judy SchnyderSenior Vice President of Clinical Operations & Data Management More Insider Trading Tools from MarketBeat Related Companies VINC Insider Buying SNGX Insider Buying MBRX Insider Buying ENSC Insider Buying COEP Insider Buying GLTO Insider Buying BIOR Insider Buying SYRS Insider Buying BCLI Insider Buying EDSA Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:GRTX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
